Voyager Therapeutics(VYGR)
LEXINGTON, MA
Biotechnology1 H-1B visas (FY2023)Focus: AAV capsid Gene Therapy
Voyager Therapeutics is a life sciences company focused on AAV capsid Gene Therapy.
Gene Therapy
Funding Stage
PUBLIC
Open Jobs
3
Pipeline & Clinical Trials
Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies
Parkinson's DiseaseClinical Trials (1)
NCT03733496Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies
N/AVenaSure
Dialysis; ComplicationsClinical Trials (1)
NCT05490225Access Cannulation Trial II
N/AVY-AADC02
Parkinson's DiseaseClinical Trials (1)
NCT03562494VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)
Phase 1VY-AADC01
Idiopathic Parkinson's DiseaseClinical Trials (1)
NCT03065192Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease
Phase 1VY-AADC01
Parkinson's DiseaseClinical Trials (1)
NCT01973543Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease
Phase 1Intraparenchymal rAAV1 -
Huntington DiseaseClinical Trials (1)
NCT04885114Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease
Phase 1Phase 1/2
Clinical Trials (1)
NCT06874621VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
Phase 1/2Leuprolide acetate
Alzheimer DiseaseClinical Trials (1)
NCT00063310ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation
Phase 2Leuprolide acetate
Alzheimer DiseaseClinical Trials (1)
NCT00076440Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study
Phase 2VP4896
Alzheimer's DiseaseClinical Trials (1)
NCT00231946ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)
Phase 3Open Jobs (3)
Interview Prep Quick Facts
Portfolio: 10 clinical trials
H-1B (2023): 1 approval
SEC Filings: 2 available
Open Roles: 3 active jobs
Financials (FY2025)
Revenue
$250M511%
R&D Spend
$92M(37%)52%
Net Income
$132MCash
$71MHiring Trend
Stable
3
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub